Wang, Meihua <br/><br/>
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?  [electronic resource] 

 -  Journal for immunotherapy of cancer  02 2019 
 - 39 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2051-1426 
<br/><br/><label>Standard No.: </label>10.1186/s40425-019-0513-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Agents, Immunological--therapeutic use<br/>Female<br/>Humans<br/>Immunotherapy<br/>Ipilimumab--therapeutic use<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Skin Neoplasms--drug therapy<br/>Survival Analysis<br/>Treatment Outcome<br/>Tumor Burden--drug effects